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Abstract
Prion diseases are disorders of protein conformation in which PrP
C, the normal cellular conformer, is converted to
an abnormal, protease-resistant conformer rPrP
Sc. Approximately 80% of rPrP
Sc accumulates in neuronal plasma
membranes where it changes their physical properties and profoundly affects membrane functions. In this review
we explain how rPrP
Sc is transported along axons to presynaptic boutons and how we envision the conversion of
PrP
C to rPrP
Sc in the postsynaptic membrane. This information is a prerequisite to the second half of this review in
which we present evidence that rPrP
Sc accumulation in synaptic regions links Notch-1 signaling with the dendritic
degeneration. The hypothesis that the Notch-1 intracellular domain, NICD, is involved in prion disease was tested
by treating prion-infected mice with the g-secretase inhibitor (GSI) LY411575, with quinacrine (Qa), and with the
combination of GSI + Qa. Surprisingly, treatment with GSI alone markedly decreased NICD but did not prevent
dendritic degeneration. Qa alone produced near normal dendritic trees. The combined GSI + Qa treatment
resulted in a richer dendritic tree than in controls. We speculate that treatment with GSI alone inhibited both sti-
mulators and inhibitors of dendritic growth. With the combined GSI + Qa treatment, Qa modulated the effect of
GSI perhaps by destabilizing membrane rafts. GSI + Qa decreased PrP
Sc in the neocortex and the hippocampus by
95%, but only by 50% in the thalamus where disease was begun by intrathalamic inoculation of prions. The results
of this study indicate that GSI + Qa work synergistically to prevent dendrite degeneration and to block formation
of PrP
Sc.
Introduction
Despite major advances in understanding prion biology
and the conversion of PrP
C to PrP
Sc, the mechanisms of
early synaptic degeneration have remained largely
unknown until now. In this review we show that accu-
mulation of the abnormal prion protein (PrP
Sc)i nn e u -
ronal plasma membranes during prion diseases directly
affects the processing of g-secretase complex substrates
and cause early dendritic degeneration.
The prion diseases in humans include sporadic
Creutzfeldt-Jakob disease (sCJD), familial CJD (fCJD),
a n dv a r i a n tC J D( v C J D ) ,t h el a s ta c q u i r e db yi n g e s t i o n
of bovine spongiform encephalopathy (BSE)-contami-
nated food. Other human prion diseases include a thala-
mic variant of CJD called sporadic and familial fatal
insomnia; kuru, acquired by ritualistic cannibalism in
aborigines of New Guinea; and Gerstmann-Sträussler-
Scheinker syndrome, a rare familial form of cerebral PrP
amyloidosis. In animals, the main prion diseases include
scrapie in sheep, which can be transmitted to rodents as
laboratory scrapie; BSE in cattle; and chronic wasting
disease in deer and elk.
Prion diseases are disorders of protein conformation
in which PrP
C, the normal cellular conformer, is con-
verted to an abnormal, protease-resistant conformer
named PrP
Sc.P r P
Sc was first described in scrapie-
infected Syrian hamsters in 1982 [1]. By convention, the
abnormal prion protein is designated PrP
Sc in all prion
diseases. sCJD is the most common prion disease,
accounting for ~85% of the total human prion cases. In
sCJD, spontaneous conversion of PrP
C to PrP
Sc begins
the process of sustained conversion of PrP
C to PrP
Sc.I n
fCJD, disease is caused by mutations of the prion pro-
tein gene (PRNP) [2]. Fewer than 1% of CJD cases are
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prion-contaminated human growth hormone prepara-
tions, human dura mater grafts, corneal transplants, and
BSE contaminated food products. In all cases of labora-
tory scrapie, disease is begun by inoculation with prions,
usually injected unilaterally into the thalamus. As a gen-
eral rule, the prions that are used in the laboratory are
obtained from a 1:10 dilution of homogenized scrapie-
infected mouse or hamster brain. In animals, injection
of synthetic PrP
Sc manufactured in E. coli also produce
disease verifying that PrP
Sc protein is the sole compo-
nent of prions [3,4].
Plasma membrane dysfunction and degeneration occur
very early in prion diseases, before the defining neuro-
pathological change of vacuolar degeneration of gray
matter. This vacuolation (spongiform degeneration) is
an intermediate step in the morphological progression
of prion disease and it precedes nerve cell death, which
is a late morphological change. The importance of the
plasma membrane in prion diseases is emphasized by
t h ef o l l o w i n gd a t a .M o r et h a n8 0 %o ft h ea b n o r m a l
prion protein, PrP
Sc, accumulates in the plasma mem-
brane [5,6]. Many of the signs and symptoms of prion
diseases are caused by dysfunction and degeneration of
specialized portions of the membrane such as synapses
[5,7,8]. The importance of plasma membrane degenera-
tion in disorders such as CJD, kuru and scrapie was first
recognized by the late Peter Lampert in 1969 [9,10].
Using electron microscopy, he found multiple foci of
neuronal membrane degeneration and no defining viral
particles. Therefore, he proposed that the plasma mem-
brane is the main target of these diseases. Twelve years
later, Stanley Prusiner found that the scrapie agent is
composed of a single, abnormal, protease-resistant
mammalian protein, the prion protein (PrP), and devoid
of nucleic acid [1]. He named this unusual agent a
“prion” and the mammalian protein that comprises the
prion, PrP
Sc. In this article, we review the evidence that
PrP
Sc accumulates in high concentration in membrane
rafts, activates Notch-1 signaling and, in doing so, pro-
motes neuronal dendritic degeneration.
Exponential increase of PrP
Sc
Prion diseases are disorders of protein conformation.
The normal cellular form of the protein, PrP
C,i s
expressed constitutively at high levels in neurons and at
low levels in glial cells [11]. PrP
C appears to be neuro-
protective and protease sensitive. It’sC - t e r m i n a lh a l f
contains 3a-helices, A, B and C and it is attached to the
outer leaf of the plasma membrane by a glycolipid
anchor. The N-terminal half is largely unstructured.
Like many glycolipid-anchored proteins, a high concen-
tration of PrP
C is found in membrane rafts [12]. In CJD
and scrapie, a protease resistant form of PrP
accumulates, PrP
Sc. It is believed that in PrP
Sc a large b-
helix forms in the middle of the PrP
C molecule eliminat-
ing all of a-helix A and a portion of a-helix B [13].
PrP
Sc causes neurodegeneration. Multiple variations in a
host animal’s amino acid sequence of PrP
Sc,v a r i a t i o n s
in the b-structure imposed on PrP
Sc, and differences in
oligomerization of PrP
Sc determine the incubation time
of the disease, the neuroanatomical distribution of
vacuolar degeneration and the host species barrier that
classically define prion strains [14].
How does the abnormal prion protein propagate? Fred
Cohen suggested a model for the conversion of PrP
C to
PrP
Sc in which he showed that when PrP
C is exposed to
PrP
Sc it acquires an identical beta structure as PrP
Sc
[ 1 5 ] .T h ep r o c e s si sn o tr e v e r s i b l e .T h ec o n v e r s i o no f
the structure from a-helix to b-helix, or in some cases
to a b-sheet is efficient, rapid and leads to an exponen-
tial increase in PrP
Sc.
PrP
Sc accumulates early in plasma membranes
The kinetics of PrP
Sc accumulation in subcellular fractions
was measured during the course of scrapie in the thalamus
and neocortex of Syrian hamsters inoculated unilaterally in
the thalamus with the Sc237 strain of scrapie prions. The
incubation time, defined as the time required to develop
clinical signs of scrapie, is ~65 days in this model. Plasma
membrane, endosomes and lysosomes were enriched in
Percoll gradients and identified with specific markers [5].
The separation of subcellular fractions was accurate since
plasma membrane, early and late endosomal, and lysoso-
mal markers were highly enriched in the respective frac-
tions. For example, Na-K ATPase was greatly enriched in
plasma membrane fractions in control and scrapie infected
Syrian hamsters. Endosomal fractions contained only
~20% of that found in membrane fractions, and none was
found in lysosomes [5]. The volume and total protein of
each fraction were monitored throughout the separation
procedure in order to calculate the total Proteinase K (PK)
resistant PrP
Sc in each fraction. A conformation-depen-
dent immunoassay (CDI) was used to measure the amount
of PrP27-30, the PK resistant peptide of PrP
Sc, in the sam-
ples [16,17]. The CDI uses sodium-magnesium phospho-
tungstate to specifically precipitate PrP
Sc and separate it
from PrP
C. About 87 amino acids are removed from the
N-terminal and a small portion of the C-terminal of PrP
Sc
(32-35 kD) by PK digestion to yield the PrP27-30 peptide.
The experiment described below was performed before we
understood that ~50% of PrP
Sc in a Syrian hamster inocu-
lated with Sc237 prions is PK sensitive (sPrP
Sc) [18]. Evi-
dence indicates that sPrP
Sc converts PrP
C to protease
resistant PrP
Sc (rPrP
Sc). Nevertheless, most of the evidence
indicates that rPrP
Sc causes the neurological dysfunction
and neurodegeneration in prion diseases, as we shall
describe in this review.
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Sc was found in plasma
membrane, endosomal and lysosomal fractions. Only a
minor amount was found outside these three fractions
(< 2%) (Fig. 1). Approximately 10-20 times more PrP
Sc
accumulated in the plasma membrane in both thalamus
(Fig. 1A) and neocortex (Fig. 1B), as compared to endo-
somes and lysosomes. A significant difference in the
kinetics of PrP27-30 was seen in the thalamus and neo-
cortex when the log of total PrP27-30 was plotted as a
function of postinoculation time. In the thalamus, where
disease was initiated by unilateral inoculation of PrP
Sc,
the conversion of PrP
C to rPrP
Sc (PrP27-30) began uni-
laterally and then spread bilaterally. PrP27-30 was
detected in the endosomal and lysosomal fractions
before it was detected in the plasma membrane fractions
(Fig. 1A). The latter is consistent with the evidence that
the conversion of PrP
C to PrP
Sc begins in the endocytic
pathway in caveolae-like domains followed by deposition
in lysosomes [19,20]. By 20 days postinoculation (dpi)
100 times more PrP27-30 accumulated in plasma mem-
branes compared to endosomes and lysosomes. From
35-65 dpi, levels of PrP27-30 in the plasma membrane,
endosomes and lysosomes reached a maximum with the
level in membranes being the highest. From this data it
appears that exogenous PrP
Sc in the inoculum under-
goes reactive endocytosis to endosomes where it induces
the conversion of PrP
C to PrP
Sc. The sequence of events
in the neocortex is different (Fig. 1B). First, rPrP
Sc was
found in all subcellular fractions at the same time and
the total amount of plasma membrane rPrP
Sc remained
10-20 times higher than levels in endosomes and lyso-
somes at every time point. This suggests that the con-
version of PrP
C to PrP
Sc took place in both the plasma
membrane and endosomes simultaneously (note: PrP
C is
protease sensitive and, therefore, does not exist in lyso-
somes). Alternatively the conversion took place only in
endosomes and transport to the plasma membrane
occurred in a recycling pathway at a rate fast enough to
hide it from our analysis. And second, levels of rPrP
Sc in
the three subcellular compartments in the neocortex
showed a simple exponential increase.
In neurons, the accumulation of rPrP
Sc in the plasma
membrane causes severe synaptic dysfunction early in the
course of disease and before the nerve cell death [7,8,21].
Accumulation of PrP
Sc early in the plasma membrane of
neocortical neurons is clearly demonstrated by peroxidase
immunohistochemistry at 42 days in the hamster model
(Fig. 2A). The membrane is filled with PrP
Sc. Only a small
amount of PrP
Sc can be seen in endosomes; however, the
results with endosomes were not quantified because the
method to enhance plasma membrane staining tended to
preclude staining of endosomes and lysosomes. rPrP
Sc in
endosomes and lysosomes is seen by double immunolabel-
ing in confocal microscopy at 56 days in the Syrian ham-
ster (Fig. 2B). We labeled PrP
Sc with green and Cat D with
red fluorescent dyes. Pretreatment of the slide with auto-
claving was adjusted to enhance endosomal and lysosomal
staining, although it was too harsh for plasma membrane
staining [22]. Three neurons at different stages of endocy-
tosis were stained. In the uppermost neuron, PrP
Sc is seen
in early endosomes. Cat D, which is characteristic of late
endosomes and lysosomes, is largely separated from early
endosome-containing PrP
Sc, although a few show a degree
of overlap with Cat D (yellow), especially in the bottom
left neuron. In the bottom right neuron, the compart-
ments containing PrP
Sc and Cat D have merged and
formed one large dystrophic-like structure at the base of
the neuron that resembles an autophagic vesicle. Electron
microscopy has confirmed that these aggregates are indeed
autophagosomes [23-25]. Large autophagic vacuoles pre-
cede or co-exist with nerve cell death at virtually all stages
of scrapie in mice, but they are most prominent in the late
stage of prion disease due to the exponential increase of
neurons forming rPrP
Sc [26]. It is not clear whether autop-
hagy plays a disease promoting role or a disease defensive
role since activation of autophagic vacuoles promotes
Figure 1 Subcellular kinetics of log total PrP27-30 (μg) in the thalamus (A) and neocortex (B) throughout the course of Sc237 scrapie
in Syrian hamster. Hamsters were inoculated intrathalamically. PrP27-30 was measured by conformation-dependent immunoassay. Percoll
gradient fractions: “plasma” membrane fraction; endosomal fraction; lysosomal fraction.
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Sc and a prolongation of incubation
time [27]. Nevertheless, this change in neurons indicates a
pre-death stage. When fixed with glutaraldehyde and par-
aformaldehyde and viewed in 1 μm thick plastic sections
by light microscopy, neurons with autophagic vesicles
appear dark (dark cell degeneration) [28]. In the hamster
neocortex, cells with dark cell degeneration accounted for
~60% of the neurons at 70 dpi with prions; whereas, in
age-matched controls they accounted for only ~10% [26].
At 42 dpi, only ~10% of neurons were dark neurons in
comparison to less than 1% of neurons in age-matched
controls. It is likely that a small number of neurons die at
all stages of disease. The few neurons that die early are
probably the neocortical neurons first infected by transy-
naptic spread of the conversion of PrP
C to rPrP
Sc whose
lysosomes become filled with rPrP
Sc.S o m eo ft h e mm a y
be interneurons with short connections. The largest num-
ber of neocortical neurons reach a pre-death stage near
t h ee n do ft h ed i s e a s ew h e nr P r P
Sc has spread exponen-
tially to many neurons in all layers of the neocortex. A
similar temporal sequence has been described in mice
where synapse degeneration precedes nerve cell death by
1-2 months [7].
We focused on the early synaptic dysfunction and
degeneration because these changes produce clinical
symptoms and because it may be possible to intervene
with drug therapy at this stage of the disease. Late-
occurring neuronal death may be treatable with
compounds that influence autophagy [27,29]. It should
be noted that most CJD patients die at an intermediate
stage of disease with vacuolization and little or no
detectable nerve cell loss [30].
rPrP
Sc is transported from one brain region to
another by axonal transport
The first evidence that rPrP
Sc is transported from one
brain region to another came from quantitative studies
of dissected brain regions. The rate of transport of
rPrP
Sc among brain regions was examined in two mod-
els of prion disease with two different incubation times.
Syrian hamsters inoculated with Sc237 prion strain have
an incubation time of ~10 weeks (Fig. 3A) [31] and
CD1 mice inoculated with the Rocky Mountain Labora-
torie’s (RML) prion strain have an incubation time ~20
weeks (Fig. 3B) [32]. The earliest and highest accumula-
tion of rPrP
Sc occurred in the thalamus in both models
and it took approximately 4 weeks for transmission of
rPrP
Sc from the thalamus to the neocortex in both mod-
els. The data suggests that rPrP
Sc spreads from one
brain region to another by very slow axonal transport
[33]. It also indicates that the rate of spread is indepen-
dent of incubation time.
Axonal transport of rPrP
Sc is clearly demonstrated by
histoblot analysis (Fig. 4). A 10 μmt h i c kf r e s hf r o z e n
section of Sc237 scrapie-infected Syrian hamster brain
was “blotted” onto nitrocellulose paper and treated with
Figure 2 Immunohistochemical localization of PrP
Sc in neurons of the neocortex in Syrian hamsters inoculated with the Sc237 prion
strain. A. A neuron in layer 4 of the neocortex at 42 days postinoculation (dpi) shows the plasma membrane filled with PrP
Sc. Peroxidase
immunohistochemistry with the PrP-specific 3F4 monoclonal antibody. B. Three neurons at 58 dpi show early endosomal, late endosomal, and
lysosomal staining for PrP
Sc (green). Goat polyclonal IgG against Cat D (red) was obtained from Santa Cruz Biosciences. Nuclei are stained blue.
See text for explanation. Bars in A represents 10 μm and in B,5μm.
DeArmond and Bajsarowicz Molecular Neurodegeneration 2010, 5:6
http://www.molecularneurodegeneration.com/content/5/1/6
Page 4 of 13PK to eliminate PrP
C. The remaining rPrP
Sc was
detected with the PrP-specific antibodies following dena-
turation with guanidinium. At 49 dpi, a sagittal section
showed the thalamus filled with rPrP
Sc (Fig. 4). At the
same time, the neocortex contained linear deposits of
rPrP
Sc in Layer 4, where the thalamocortical axons ter-
minate. These deposits became visible when a suffi-
ciently large number of presynaptic boutons and
postsynaptic neurons acquired rPrP
Sc.
This evidence suggests a very slow axonal transport
system requiring ~4 weeks to travel 3-5 mm and pre-
cludes any of the active transport systems, which take
only hours to days. We believe PrP
Sc diffuses passively
along the axon membranes, driven by a concentration
gradient that is higher near the cell body in the thala-
mus and is progressively lower towards neocortex [33].
Alternatively, as rPrP
Sc diffuses into axons it may con-
vert adjacent axonal PrP
C molecules into sPrP
Sc or
rPrP
Sc resulting in the continuous conversion process
that eventually reaches presynaptic boutons.
Axonal terminals and transynaptic conversion of
PrP
C to PrP
Sc
Electron microscopy has shown that PrP
C is located ubi-
quitously throughout the plasma membrane, which
includes synaptic boutons and postsynaptic membranes;
PrP
C was not found on synaptic vesicles [34]. Since the
ultrastructural location of rPrP
Sc is less well known, we
must infer its location from synaptosomal immunohisto-
chemistry (Fig. 5), from immunohistochemistry of tissue
sections (Figs. 2A, 4) and from the kinetics of PrP
Sc
(Fig. 3). It seems that rPrP
Sc is present in high concen-
trations on the surface of the presynaptic bouton, as the
result of axonal transport [33].
To examine PrP
Sc accumulation in the presynaptic
boutons we prepared synaptosomes from the neocortex
of Syrian hamsters at 70 dpi. Synaptosomes, which con-
tain presynaptic boutons and postsynaptic membranes,
were stained for rPrP
Sc (green) and synaptophysin (red)
[5] (Fig. 5). Synaptophysin is one of the specific markers
for synaptic vesicles in presynaptic boutons. rPrP
Sc
appears to be on the surface of the synaptosomes as
well as in the interior (Fig. 5). The majority of the
objects in the figure were also immunostained for
synaptophysin as seen in the merged image (Fig. 5). The
similarity of the immunohistochemistry for PrP
Sc and
synaptophysin suggest that some PrP
Sc is located within
the axon terminals. Not all of the PrP
Sc positive struc-
tures were synaptophysin positive. They probably repre-
sent fragments of plasma membrane contaminants.
Figure 3 PrP
Sc is transported along axons from one brain
region to another. Data from the thalamus (squares) and the
neocortex (triangles) are shown. A. Syrian hamsters inoculated in
the thalamus with the Sc237 prion strain become clinically ill at ~10
weeks. Measurements of rPrP
Sc were generated by Western blot
analysis from dissected brain regions. B. CD1 mice inoculated in the
thalamus with RML prions become clinically ill at ~20 weeks. rPrP
Sc
was estimated by morphometry of brain regions on histoblots.
Figure 4 Histoblot of Syrian hamster brain sagittal section at
49 dpi after inoculation with the Sc237 prion strain. rPrP
Sc was
stained with PrP-specific 3F4 antibodies. See text for explanation.
Adapted from Bouzamondo-Bernstein et al. [5].
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C to PrP
Sc begins in the postsy-
naptic membrane and continues to be formed in the
postsynaptic neurons by one of two possible mechan-
isms: degeneration of the presynaptic bouton [5,21] or
release of PrP
Sc during synaptic transmission. Once it
traverses the synaptic cleft, it can bind to PrP
C on the
postsynaptic membrane and convert it to rPrP
Sc,p o s s i -
bly in endosomes by endocytosis of PrP
C-PrP
Sc complex.
Dendritic degeneration occurs early in prion
disease
CD1 mice inoculated unilaterally in the thalamus with
RML prions show early regressive changes in dendrites
70 to 80 days before the mice became clinically ill with
scrapie at ~130 dpi [35]. At this time, dendrites of neo-
cortical pyramidal neurons showed remarkable regres-
sive changes in scrapie-infected mice compared to age-
matched controls (Fig. 6A). We quantified the length of
the pyramidal neuron dendrites in the neocortex
throughout the course of scrapie and compared them
with age-matched normal controls (Fig. 6B). At 30 dpi,
the control and infected mice had similar dendrite
lengths. Both control and infected animals showed den-
drite growth as they matured, but in the infected ani-
mals the dendritic growth was much slower. From 50-
130 dpi there was significant decrease in dendritic
length in mice infected with prions, compared to age
matched controls. The dendritic degeneration increased
to 50% by 130 dpi. A similar finding was made for the
number of dendritic branches (data not shown). It
should be noted that the regressive dendritic changes
began early in the neocortex, between 30 and 50 dpi,
and before vacuolization, which occurred at 80 to 90
d p i .T h ed a t ai n d i c a t et h a td e n dritic regressive changes
are among the earliest morphological feature in prion
disease. However, it is reported that C57BL/6 mice
inoculated bilaterally in the hippocampus with the ME7
p r i o ns t r a i ns h o w e do n l yd e c r e a s e de x p r e s s i o ni np r o -
teins of the presynaptic compartment and degeneration
of hippocampal presynaptic boutons and no dendritic
degeneration [21]. The authors report intact dendritic
cytoarchitecture based on the b-tubulin immunostain-
ing; however, the lengths of dendrites and branching
were not reported and their findings are difficult to
assess from their photomicrographs.
Notch-1 signaling in prion diseases
During embryonic development of the central nervous
system, regressive changes in dendrites are regulated by
a Notch-1 signaling pathway [36,37]. Activation of
Notch-1 stimulates the HES and HERP families of inhi-
bitor effecter proteins [38], which in turn inhibit pro-
neuronal genes that maintain the length and branching
of dendrites. During development, ligands such as
Delta-like and Jagged expressed on adjacent cells lead to
the truncation of Notch-1 [39]. The truncated Notch-1
is a specific ligand for Nicastrin, which is 1 of the 4 pro-
teins that comprise g-secretase complex. Nicastrin car-
ries the truncated Notch-1 into the g-secretase complex
where it cleaves off the active molecule called the
Notch-1 intracellular domain, NICD [40,41]. NICD is
translocated to neuronal nuclei where it activates the
HES and HERP genes that inhibit the expression of pro-
neuronal genes that maintain dendrites. We speculated
that if this pathway were active in prion disease, we
might find increased amounts of NICD and perhaps
changes in the g-secretase complex itself.
The first evidence that the Notch-1 pathway might be
important in prion disease was the finding that the for-
mation of NICD is associated with rPrP
Sc accumulation
Figure 5 Colocalization of total PrP
Sc (rPrP
Sc +s P r P
Sc) and synaptophysin in synaptosomes. Confocal micrographs of a “crude”
synaptosomal preparation obtained from the Sc237 prion strain infected hamsters at 70 dpi show total PrP
Sc (green) and synaptophysin (red)
(mouse monoclonal anti-synaptophysin, clone SY38, DakoCytomation). Merged images show colocalization of total PrP
Sc and synaptophysin in
yellow. Bar represents 20 μm. Adapted from Bouzamondo-Bernstein et al. [5].
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increased rapidly between 30 and 50 dpi, which corre-
sponded to the period when dendrites showed the first
signs of regression (Fig. 6B). During that period the for-
mation of NICD correlated well with rPrP
Sc accumula-
tion in membranes of neocortical synaptosomes (Fig.
7A). The correlation suggested that rPrP
Sc was responsi-
ble for the truncation of Notch-1 rather than a ligand
such as Delta-like or Jagged. In scrapie infected mice,
NICD was translocated to the neuronal nucleus (Fig.
7C), whereas in control mice, low levels of NICD were
located mostly in neuronal cytoplasm (Fig. 7B).
The increasing NICD curve was triphasic (Fig. 8B).
After an initial rapid increase of NICD at 30-50 days,
the NICD level plateaued between 50-90 days and then
resumed a rapid increase at 90-130 days. Nicastrin, the
molecule that transports truncated Notch-1 to the g-
secretase complex, showed a delayed increase, which
corresponds to the late increase of NICD level from 90-
130 dpi (Fig. 8A, B). This suggests that between 60 and
100 days truncated Notch-1 was being formed at a faster
rate than Nicastrin could transport it to g-secretase and
that all of the available Nicastrin molecules had become
saturated with truncated Notch-1. From 90-130 days,
when Nicastrin levels increased 2 fold, the rate of for-
mation of NICD increased accordingly. We do not
know what caused the membrane concentration of
Nicastrin to rise. Presenilin-1, the g-secretase compo-
nent that cleaves NICD from truncated Notch-1,
showed a decrease or no change at all (Fig. 8A).
Cholesterol rich membrane rafts: Hypothesis
In normal control brains PrP
C, Notch-1 and g-secretase
are concentrated in membrane rafts [42]. Similarly, in
prion infected brains PrP
Sc (sPrP
Sc and/or rPrP
Sc),
Notch-1 and g-secretase are concentrated in membrane
rafts. How then does PrP
Sc lead to formation of NICD?
We can only guess at this time. The data suggest that
PrP
Sc causes truncation of Notch-1 in a dose depen-
dent manner, probably without participation of Delta-
like or Jagged ligands. Nicastrin transports the trun-
cated Notch-1 to the g-secretase complex. From these
data we propose a null hypothesis that inhibition of
NICD formation during prions disease will prevent
dendritic degeneration. As we shall see, this hypothesis
fails to account for the complexity of g-secretase
functions.
Treatment strategy
We obtained g-secretase inhibitor (GSI) LY411575 from
Drs. Todd Golde and Pritam Das at the Mayo Clinic,
Jacksonville, Florida. This is a particularly potent Notch-
1 inhibitor. Like many GSI’s designed to treat Alzhei-
mer’sd i s e a s e ,i tp r o d u c e ss e v e r e gastrointestinal tract
and immune system toxicity; therefore, it is not used
clinically. However, we believed it could be used for pre-
clinical proof of concept studies. We also planned to
combine quinacrine (Qa) with GSI because Qa was
found to clear all PrP
Sc from scrapie-infected ScN2a
cells within 5 days [43]. It was our belief that any reduc-
tion of PrP
Sc in brain caused by Qa would be additive to
the GSI effect in terms of reducing NICD formation and
dendrite degeneration.
Wild type CD1 mice were inoculated in the thalamus
with RML prions. Oral doses of GSI alone (5 mg/kg/
day), Qa alone (40 mg/kg/day) and combined GSI + Qa
(same doses) were prepared in a nutritional chocolate
drink containing 0.007% DMSO. The treatment was
started at 50 dpi when disease was well established in
the thalamus and had just begun to spread to the
Figure 6 Progressive degeneration of dendrites during prion disease occurs early in the incubation time [35]. CD1 mice were inoculated
in the thalamus with RML scrapie prions. A. Representative Golgi silver impregnation of dendrites in the neocortex show severe atrophy in
scrapie-infected mice compared to controls. B. Apical dendritic length versus incubation time in age matched controls (open circles) and in
scrapie (closed circles) is shown during the course of scrapie. Adapted from Ishikura et al. [35].
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Page 7 of 13neocortex. Because of GSI toxicity, continuous treat-
ment had to be terminated after 43 to 55 days.
Effect of treatment on dendrites
Pharmacological reduction of PrP
Sc is clinically mean-
ingful only if it prevents neurodegeneration. To quantify
the dendrite loads, dendrites and nerve cell bodies were
stained by the Golgi silver impregnation method. Mea-
surements of dendrite loads were obtained from layer 6
of the neocortex, the CA1 region of the hippocampus
and the medial thalamus (Fig. 9A-C). We measured the
total number of dendrites and nerve cell bodies using
BioQuant® software (Fig. 9D-F). After 43 days, three
age-matched control mice showed richly branched den-
dritic trees in all 3 regions. In untreated RML prion-
infected mice, dendrite shortening and a decrease in the
number of dendrite branches were severe in all 3
regions. Surprisingly, 43 days of treatment with GSI
alone had no effect on the dendritic trees; they remained
as atrophied as in untreated RML-infected animals. In
contrast, Qa alone produced near normal dendritic
trees. And, combined GSI + Qa treatment resulted in
significantly more dendrites and a richer dendritic tree
than controls. These results were unexpected to us. We
thought GSI would have a very positive effect on den-
drite lengths and number of branches. We believed Qa
would produce no effect.
There are 20-30 substrates cleaved by the g-secretase
complex. Notch-1 is the best-known inhibitor of
Figure 7 rPrP
Sc accumulation in neocortical synaptosomes coincide with increased amounts of NICD and translocation of NICD to
neuronal nuclei. A. Kinetics of the log of neocortical rPrP
Sc accumulation in synaptosomes (open squares) relative to NICD concentration (filled
circles). NICD levels in age matched PBS-inoculated mice are shown as controls (open circles). B. In control mice, confocal microscopy shows
small amounts of NICD mostly in the cytoplasm in uninfected neocortical neurons. C. Confocal microscopy shows accumulation of NICD in the
nuclei of cortical neurons in RML infected mice at 140 dpi. NICD (green) is detected by Notch-1 Val-1744 antibody from Cell Signaling
Technology and the neuron specific antibody anti-NeuN (red) is from Chemicon. In A, data points are calculated from three independent
experiments. ** P < 0.005; *** P < 0.0001 by Student’s t test. Adapted from Ishikura et al. [35].
Figure 8 Triphasic NICD response to rPrP
Sc accumulation
corresponds with delayed increased expression of Nicastrin. A.
Western blots during the course of RML scrapie show decreased
amount of PS-1 (Presenilin 1) and increased amount of Nicastrin
relative to GAPDH standard. B. NICD and Nicastrin are plotted as a
function of incubation time. The initial steep rise in NICD
corresponds to rPrP
Sc accumulation, followed by relatively flat NICD
level. The late occurring rise in NICD corresponds to increased
expression of Nicastrin. n = 3 mice at each time point.
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Page 8 of 13dendritic growth [44,45]. Two g-secretase substrates that
stimulate dendritic growth are ErbB-4 [46,47] and
EphA4 [42]. Whether or not more stimulators and inhi-
bitors will be found has yet to be determined. In the
context of these considerations and to better understand
our results we plotted dendrite load versus the concen-
tration of NICD in neocortex (Fig. 10). For detection of
NICD, nuclei were enriched using the Nuclear EZ prep
according to kit instructions. Anti-NICD Val 1744 (Cell
Signaling Technology) was used as a primary antibody
for Western blots.
Control mice normally express a small amount of
NICD (Fig. 10A). In the dendrite load versus NICD level
plot, control NICD levels are associated with abundant
dendrites indicating a balance between stimulators and
inhibitors (Fig. 10B). In the untreated RML infected
mice, a 3 to 4 fold increase of NICD was associated
with a marked reduction in the dendrite load as seen in
the graph. This suggests that prion infection shifted the
balance toward inhibition. GSI alone was associated
with a very low NICD level, as expected, but dendritic
trees showed no recovery (Fig. 9), which argues that GSI
inhibited both g-secretase stimulators and inhibitors of
dendritic growth. Combined GSI + Qa treatment
resulted in an almost normal NICD level and a greater
than control dendritic arborization (Fig. 10). This sug-
gests that Qa was able to modulate the effect of GSI. Qa
“destabilizes” membrane rafts by redistributing choles-
terol from the plasma membrane to endosomes and
lysosomes [48]. We speculate that perhaps Qa also sepa-
rates PrP
Sc from Notch-1 or separates components of
the g-secretase complex from each other. Qa alone
doubled NICD levels compared to controls and was
associated with a near normal dendritic load (Fig. 10).
To accomplish this, Qa must have also proportionately
increased the stimulators of dendritic growth. The data
demonstrate that GSI + Qa work synergistically to regu-
late the maintenance of dendrite size and shape in prion
disease. Furthermore, these data argue that the g-secre-
tase complex plays a major role in the early dendritic
changes.
GSI + Qa treatment decreases rPrP
Sc
GSI + Qa resulted in a 95% decrease of rPrP
Sc in neo-
cortex and hippocampus (Fig. 11A, B). In the thalamus,
where prion replication was initiated, GSI + Qa reduced
rPrP
Sc levels by only ~50% (Fig. 11C). This suggested
that ~50% of rPrP
Sc in the thalamus could not be
cleared by GSI + Qa. Histoblot showed that most of the
residual rPrP
Sc was located in white matter tracts in and
Figure 9 Combined GSI + Qa treatment prevented dendritic degeneration more effectively than GSI or Qa alone. A-C. Golgi silver
staining in dendrites in layer 6 of the cortex (A), hippocampal CA1 region (B), and the medial nuclei of the thalamus (C). D-F. Bar graphs of the
dendrites load in the three regions respectively as determined by morphometry. RML infected untreated mice (UnTx) shows severe dendritic
atrophy. Prevention of dendritic loss was associated with GSI + Qa treatment. Measurements of dendrite loads in each of the three brain regions
are shown as a function of the treatment. Student t test probabilities (n = 3 mice each): * P ≤ 0.05; **P ≤ 0.01. Scale bars represent 30 μm and
apply to each image in the same row. Adapted from Spilman et al. [8].
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Page 9 of 13around the thalamus (Fig. 12). In untreated scrapie at 43
days (93 dpi), PrP
Sc fills the entire thalamus including
the grey and white matter, and lower amounts of rPrP
Sc
are also found in the hippocampus and neocortex (Fig.
12A). In addition, rPrP
Sc is located in long tracts con-
necting the thalamus with other regions. With GSI +
Qa treatment for 43 days, most of rPrP
Sc has been
cleared from the grey matter of the thalamus as well as
from the hippocampus and neocortex (Fig. 12B). Most
remaining rPrP
Sc is located in white matter tracts pas-
sing through the thalamus and those connecting the
thalamus with the other regions. In the thalamus where
the disease was started, it appears that some rPrP
Sc
entered the white matter before treatment was begun.
Residual rPrP
Sc in white matter can restart the
disease
In a second GSI experiment, mice were treated with GSI
+ Qa for 28 days, which was sub lethal (Fig. 13). We
found that rPrP
Sc was cleared from the grey matter of
the thalamus within a day or two of the start of treat-
ment (Fig. 13B), but low levels of rPrP
Sc persisted in the
white matter tracts during treatment and for 21 days
thereafter. A sharp rebound of the conversion of PrP
C
to rPrP
Sc in the thalamus (Fig. 13B) and to a lesser
extent in the neocortex (Fig. 13A) began 21 days after
the end of treatment, which suggested that the surviving
rPrP
Sc was able to restart the disease. It also appears
that GSI + Qa altered or greatly decreased axonal trans-
port of rPrP
Sc to other brain regions based on the
response in the neocortex, which only showed a slight
increase in rPrP
Sc at 21 days after the end of treatment.
The implication of these findings is that a shorter period
of oral treatment with the GSI (LY411575) + Qa is tol-
erable and can hold the disease in check. New GSIs
with less toxicity may become available, which will per-
mit longer treatment. In the meantime, we intend to
explore whether a short oral course of GSI + Qa in
combination with gene therapy could stop disease pro-
gression. Adding concomitant gene therapy to the thala-
mus with a short interfering RNA (siRNA) against PrP
C
theoretically will give long-term control of the disease
by removing the substrate for rPrP
Sc formation.
Conclusions
In this review we focused on the exponential accumula-
tion of rPrP
Sc in the plasma membrane of neurons and
how it causes regressive changes in dendrites. We did
not review the additional evidence from our laboratory
that rPrP
Sc was associated with decreased evoked release
of neurotransmitters from neocortical synaptosomal pre-
parations during scrapie in Syrian hamsters and that it
Figure 10 The three treatments had significantly different
effects on nuclear NICD levels and dendritic degeneration in
the cortex. A. Western blot analysis shows nuclear NICD levels from
prion infected CD1 mice after treatment with Qa alone, GSI alone
and Qa + GSI. For controls, nuclear NICD levels in an uninfected
mouse (Control, C) and in an untreated RML prion infected mouse
(UnTx) are shown. B. Relative NICD levels are plotted as a function
of dendritic load (see Fig. 9D). See text for discussion. Error bars for
both dendrite load and NICD (n = 3 mice each) are shown [8].
Figure 11 Combined GSI + Qa therapy reduced rPrP
Sc in prion
infected CD1 mice by 95% in the neocortex and hippocampus
and by 50% in the thalamus. Western immunoblots of rPrP
Sc in
the neocortex (A), hippocampus (B), and thalamus (C) are shown.
Adjacent bar graphs show densitometry estimates of the relative
rPrP
Sc levels in the respective Western blots (integrated optical
density units per milligram of total protein). Means and standards
deviation are shown. Student’s t test probability (n = 3 mice each): *
P ≤ 0.05; ** P ≤ 0.01. Adapted from Spilman et al. [8].
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Page 10 of 13was associated with presynaptic bouton degeneration
[5]. In other experiments, accumulation of rPrP
Sc in
membranes in mouse scrapie decreased binding of spe-
cific ligands to receptors on the postsynaptic membrane
[49,50]. Accumulation of rPrP
Sc in the plasma mem-
brane of a scrapie-infected N2a cell line (ScN2a) was
found to decrease membrane fluidity by 7-fold com-
pared to uninfected N2a cells [51,52]}. A similar change
in neuronal membrane properties was reported for
synaptosomal membranes [53]. These data argue that
the early accumulation of rPrP
Sc in neuronal plasma
membranes should not be ignored. Finally, the impor-
tance of lipid raft domains must be emphasized because
g-secretase [42], Notch-1, and the glycolipid-anchored
proteins (PrP
C,a n dP r P
Sc), all are concentrated within
rafts. This most likely explains why quinacrine and the
g-secretase inhibitor work synergistically to decrease
rPrP
Sc and to prevent dendritic degeneration. The data
suggest that dendritic degeneration is mediated by the
g-secretase complex. Furthermore, the response of PrP
Sc
to GSI + Qa raises the possibility that the conversion of
PrP
C to PrP
Sc is also mediated, at least in part, by the g-
secretase system.
Acknowledgements
We thank Bernadette DeArmond, MD, MPH, for editing the manuscript. This
work was funded by National Institutes of Health Grants AG10770, AG02132,
AG021601 and NS041997, and by the Stephen and Patricia Schott Family
Fund.
Author details
1Department of Pathology, University of California San Francisco, 1855
Folsom Street MCB 269, San Francisco, CA 94143-0803, USA.
2Institute for
Neurodegenerative Diseases, 1855 Folsom Street MCB 505, University of
California San Francisco, San Francisco, CA 94143-0803, USA.
Figure 12 rPrP
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were taken from RML-infected mice at 93 dpi untreated (A) and treated with GSI + Qa for 43 days (B). CC, corpus callosum; f, fimbria of fornix;
Hp, hippocampus; IC, internal capsule; Nc, neocortex; Th, thalamus. Adapted from Spilman et al. [8].
Figure 13 After 28 days of treatment with GSI + Qa, rPrP
Sc
levels remain low for an additional 21 days after treatment is
ceased. Estimates of rPrP
Sc concentration (n = 3 mice) in the
neocortex (A) and thalamus (B) are given. Relative PrP
Sc levels from
untreated infected mice at 78, 85, 92 and 99 dpi were estimated by
using data from an earlier study [32]. Adapted from Spilman et al.
[8].
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